Aimmune Therapeutics Agrees to $2 Billion Nestle Tender Offer
Aimmune Therapeutics shareholders have officially backed Nestle’s $2 billion tender offer, effectively making them owners of the first US-approved peanut allergy treatment.
Once the deal is complete, Nestle will control approximately 84% of outstanding shares as of the $34.50 per share offer's expiration date, completing the transaction that has long been on the table, but got slowed down by the coronavirus pandemic.
*The products advertised are only available to clients under Fondex Limited Seychelles (SDL No: SD037).
Cookies on Fondex
These cookies fall under the following categories: essential, functional and marketing cookies. Marketing cookies may also include third-party cookies.
You can customize your selection of which cookies you want to accept.
These cookies are necessary for the website to function correctly and cannot be switched off.
Functional cookies allow the website to remember users' preferences and the choices you make on the website such as username, region, and language.